Dudediligence.

Insmed Incorporated

INSMNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$93.4MSep ’24$104.4MDec ’24$92.8MMar ’25$107.4MJun ’25$142.3MSep ’25$263.8MDec ’25$306.0MMar ’26$425.5MJun ’26
Net income, by quarter
−$220.5MSep ’24−$235.5MDec ’24−$256.6MMar ’25−$321.7MJun ’25−$370.0MSep ’25−$328.5MDec ’25−$163.6MMar ’26−$13.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$188.5M$245.4M$305.2M$363.7M$606.4M
Gross profit$144.3M$190.2M$239.6M$278.0M$483.5M
Operating income−$375.1M−$457.3M−$709.6M−$878.3M−$1.25B
Net income−$434.7M−$481.5M−$749.6M−$913.8M−$1.28B
Operating cash flow−$363.3M−$400.4M−$536.2M−$683.9M−$935.0M
Free cash flow−$370.6M−$410.3M−$549.5M−$705.8M−$967.6M
Cash$716.8M$1.07B$482.4M$555.0M$510.4M
Debt$566.6M$1.13B$1.16B$1.10B$541.0M
Shares outstanding118.7M135.7M148.0M179.4M214.3M